Vancomycin

May be taken with or without food.

Hypersensitivity.

Patient with inflammatory disorders of the intestinal mucosa or Clostridioides difficile-induced pseudomembranous colitis, underlying hearing loss; anuria, allergic reactions to teicoplanin. Oral vancomycin is only indicated for specific types of infection; recommendations may vary among countries, refer to country-specific guidelines. Avoid rapid infusion. Avoid use in patients with previous hearing loss. Renal impairment. Neonates, children, and elderly. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor CBC, LFTs, urine, and serum trough vancomycin concentration periodically. Serial monitoring of renal function and auditory function should be performed. Monitor for signs and symptoms of skin reactions.

Significant: Fungal or bacterial superinfection (prolonged use); transient or permanent ototoxicity, deafness preceded by tinnitus; nephrotoxicity (reversible), may lead to acute renal failure; infusion-related reactions (e.g. hypotension, "red man syndrome", urticaria, pruritus); extravasation (may occur with necrosis), thrombophlebitis; Clostridium difficile associated diarrhoea (IV). Blood and lymphatic system disorders: Neutropenia (reversible), thrombocytopenia. Gastrointestinal disorders: Nausea; abdominal pain, diarrhoea, flatulence, vomiting (oral). General disorders and administration site conditions: Fever, chills, fatigue; peripheral oedema (oral). Metabolism and nutrition disorders: Hypokalaemia (oral). Musculoskeletal and connective tissue disorders: Muscle spasm (chest and back), back pain. Nervous system disorders: Headache. Renal and urinary disorders: UTI. Rarely, interstitial nephritis. Respiratory, thoracic and mediastinal disorders: Dyspnoea, stridor. Vascular disorders: Decrease in blood pressure; vasculitis.
Potentially Fatal: Hypersensitivity reactions, severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP), linear IgA bullous dermatosis (LABD); Clostridium difficile colitis (IV).

Increased frequency of erythema, histamine-like flushing, and anaphylactic reactions with anaesthetic agents. May enhance anaesthetic-induced myocardial depression. May reduce the efficacy of oral contraceptives. Concomitant use with other potentially ototoxic, neurotoxic, or nephrotoxic drugs (e.g. aminoglycosides, amphotericin B, polymyxin B, bacitracin, colistin, piperacillin/tazobactam, cisplatin, loop diuretics, NSAIDs) may potentiate the toxicity of vancomycin. Bile acid sequestrants (e.g. colestyramine) may diminish the therapeutic effect of oral vancomycin; administer several hours apart. May enhance the neuromuscular-blocking effect of neuromuscular-blocking agents (e.g. suxamethonium, vecuronium).

Other Antibiotics

S01AA28 - vancomycin
A07AA09 - vancomycin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
J01XA01 - vancomycin ; Belongs to the class of glycopeptide antibacterials. Used in the systemic treatment of infections.